Treace Medical Concepts, Inc. (TMCI)

Market Cap	117.61M -73.7%
Revenue (ttm)	212.69M +1.6%
Net Income	-59.00M
EPS	-0.93
Shares Out	64.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	446,824
Open	1.890
Previous Close	1.870
Day's Range	1.745 - 1.910
52-Week Range	1.170 - 7.780
Beta	0.88
Analysts	Hold
Price Target	4.77 (+162.09%)
Earnings Date	May 5, 2026

About TMCI

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percupla...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 23, 2021
• Employees: 450
• Stock Exchange: NASDAQ
• Ticker Symbol: TMCI
• Website: https://www.treace.com

Financial Performance

In 2025, Treace Medical Concepts's revenue was $212.69 million, an increase of 1.59% compared to the previous year's $209.36 million. Losses were -$59.00 million, 5.85% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for TMCI stock is "Hold." The 12-month stock price target is $4.77, which is an increase of 162.09% from the latest price.

Price Target

$4.77

(162.09% upside)

Analyst Consensus: Hold